Table 1 In vitro evidence for roles of UBXDF in cancers
Protein | Cancer type | cell line | Effects | Mechanisms | References |
|---|---|---|---|---|---|
UBXN10 | Colon adenocarcinoma | FHC, HCT116, SW480 and SW620 | Inhibits proliferation and migration | Modulates the miR-515-5p/SLIT3 axis | [66] |
UBXN2A | Colorectal cancer | HCT-116, LoVo, MCF7, U2OS, HeLa and HepG2 | Promotes apoptosis, inhibits proliferation | Regulates the protein level of mot-2 | [67] |
UBXN2A | Colorectal cancer | HCT116, LoVo, SW-480 and U2OS | Promotes cell death | Regulates the oncoprotein mot-2 | [68] |
UBXN2A | Colorectal cancer | HCT-116 and LoVo | Promotes apoptosis | Regulates the oncoprotein mot-2 | [39] |
UBXN2A | Colorectal cancer | HEK293, HeLa, HCT-116, MCF7, SW48, HT-29, SW620, T84 and HUVEC | Promotes apoptosis, inhibits cell growth | A p53-dependent pathway | [69] |
UBXN2A | Osteosarcoma | HEK-293T, HCT-116, LoVo and U2OS | Promotes apoptosis, inhibits proliferation and migration | The mortalin oncoprotein pathway | [70] |
UBXN8 | Hepatocellular carcinoma | HepG2, Hep3B, HuH1, HuH7, SMMC7721, SNU182, SNU387, SNU449, PLC/PRF/5 and Sk-Hep-1 | Inhibits cell growth | Regulates the expression of cell cycle negative regulators TP53 and p21CIP1/WAF1 | [71] |
UBXN7 | Hepatocellular carcinoma | HEK293, Huh7 and HepG2 | Inhibits autophagy | NF-κB signalling pathway | [72] |
UBXN7 | Lung squamous cell carcinomas | H520, HCC95, H2882, HCC15, H157 and SW900 | Promotes cell growth | Identification of candidate drivers in Chromosome 3q26-29 | [73] |
FAF1 | Breast cancer | / | Inhibits invasion and metastasis | TGF-β signalling pathway | [74] |
FAF1 | Breast cancer | HEK293T, HeLa, MCF7, MDA-MB-231 and MDA-MB-435 | Promotes cell growth | TGF-β signalling pathway | [75] |
FAF1 | Breast cancer | HEK293, HeLa, MCF7 and MDA-MB-23 | Inhibits migration | Wnt/β-catenin signalling pathway | [76] |
FAF1 | Colorectal cancer | DLD-1 | Promotes apoptosis | NF-κB and Wnt signalling pathway | [44] |
FAF1 | Cervical cancer | HEK293T and HeLa | Inhibits tumor formation | Regulates the degradation of Hsp70 | [77] |
FAF1 | Clear cell renal cell carcinoma | SRD-13 A and HEK-293 | Inhibits cell growth | Regulates the degradation of β-catenin | [78] |
FAF1 | Lung cancer | A549 and H1299 | Inhibits cell growth, migration and invasion, promotes apoptosis | Wnt signalling pathway | [79] |
FAF1 | Gastric cancer | HGC-27 | Promotes cell death and apoptosis | Primarily biochemical pathways | [80] |
FAF1 | Gastric cancer | HGC-27 | Inhibits proliferation and growth, promotes apoptosis | NF-κB signalling pathway | [81] |
FAF1 | Gastric cancer | BOSC23 and HeLa | Promotes apoptosis | NF-κB signalling pathway | [82] |
FAF1 | Non-small cell lung carcinomas | A549, H460, H1299, H1650 and SPC-A1 | Inhibits proliferation, invasion and migration, promotes cell cycle arrest and apoptosis | TGF-β signalling | [83] |
FAF1 | Ovarian cancer | / | Negative correlation with HSP70 expression | NF-κB and ubiquitin proteasomal pathways | [84] |
FAF1 | Prostate cancer | 293T, HeLa, HGC-27, MGC-803 and DU-145 | Promotes apoptosis | Correlates with the amount of miR-24 | [85] |
UBXN1 | BRCA1 tumour | 293 cells | Inhibits the enzymatic function of BRCA1 | BRCA1 pathway | [86] |
UBXN1 | Colon adenocarcinoma | SW480 and HT29 | Inhibits cell growth and tumorigenesis | Regulates IκBα levels and the nuclear levels of NF-κB and p-NF-κB | [87] |
UBXN1 | Diffuse gliomas | H4, LN229 and U87 | Inhibits proliferation and migration | NF-κB signalling pathway | [88] |
UBXN1 | Glioblastoma | N33 and U87-MG | Inhibits cell growth and tumorigenesis | NF-κB signalling pathway | [87] |
UBXN1 | Glioblastoma | U87 and LN229 | Inhibits cell growth | Regulates the level of NF-κB | [89] |
UBXN1 | Prostate cancer | PC3, LNCaP, 22Rv1 and DU145 | Promotes proliferation, migration and invasiveness | PI3K/Akt/NF-κB Pathway | [90] |